879 related articles for article (PubMed ID: 30429343)
21. HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial.
Bart PA; Huang Y; Karuna ST; Chappuis S; Gaillard J; Kochar N; Shen X; Allen MA; Ding S; Hural J; Liao HX; Haynes BF; Graham BS; Gilbert PB; McElrath MJ; Montefiori DC; Tomaras GD; Pantaleo G; Frahm N
J Clin Invest; 2014 Nov; 124(11):4843-56. PubMed ID: 25271627
[TBL] [Abstract][Full Text] [Related]
22. Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen.
Knudsen ML; Ljungberg K; Tatoud R; Weber J; Esteban M; Liljeström P
PLoS One; 2015; 10(2):e0117042. PubMed ID: 25643354
[TBL] [Abstract][Full Text] [Related]
23. Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial.
Pantaleo G; Janes H; Karuna S; Grant S; Ouedraogo GL; Allen M; Tomaras GD; Frahm N; Montefiori DC; Ferrari G; Ding S; Lee C; Robb ML; Esteban M; Wagner R; Bart PA; Rettby N; McElrath MJ; Gilbert PB; Kublin JG; Corey L;
Lancet HIV; 2019 Nov; 6(11):e737-e749. PubMed ID: 31601541
[TBL] [Abstract][Full Text] [Related]
24. Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial.
Lévy Y; Lacabaratz C; Ellefsen-Lavoie K; Stöhr W; Lelièvre JD; Bart PA; Launay O; Weber J; Salzberger B; Wiedemann A; Surenaud M; Koelle DM; Wolf H; Wagner R; Rieux V; Montefiori DC; Yates NL; Tomaras GD; Gottardo R; Mayer B; Ding S; Thiébaut R; McCormack S; Chêne G; Pantaleo G
PLoS Pathog; 2020 Jun; 16(6):e1008522. PubMed ID: 32589686
[TBL] [Abstract][Full Text] [Related]
25. Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants.
Burton S; Spicer LM; Charles TP; Gangadhara S; Reddy PBJ; Styles TM; Velu V; Kasturi SP; Legere T; Hunter E; Pulendran B; Amara R; Hraber P; Derdeyn CA
J Virol; 2019 Apr; 93(7):. PubMed ID: 30651354
[TBL] [Abstract][Full Text] [Related]
26. Cross-protection in NYVAC-HIV-1-immunized/HIV-2-challenged but not in NYVAC-HIV-2-immunized/SHIV-challenged rhesus macaques.
Patterson LJ; Peng B; Abimiku AG; Aldrich K; Murty L; Markham PD; Kalyanaraman VS; Alvord WG; Tartaglia J; Franchini G; Robert-Guroff M
AIDS; 2000 Nov; 14(16):2445-55. PubMed ID: 11101054
[TBL] [Abstract][Full Text] [Related]
27. Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk.
Fouda GG; Amos JD; Wilks AB; Pollara J; Ray CA; Chand A; Kunz EL; Liebl BE; Whitaker K; Carville A; Smith S; Colvin L; Pickup DJ; Staats HF; Overman G; Eutsey-Lloyd K; Parks R; Chen H; Labranche C; Barnett S; Tomaras GD; Ferrari G; Montefiori DC; Liao HX; Letvin NL; Haynes BF; Permar SR
J Virol; 2013 Jun; 87(12):6986-99. PubMed ID: 23596289
[TBL] [Abstract][Full Text] [Related]
28. The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1.
Raman SC; Mejías-Pérez E; Gomez CE; García-Arriaza J; Perdiguero B; Vijayan A; Pérez-Ruiz M; Cuervo A; Santiago C; Sorzano COS; Sánchez-Corzo C; Moog C; Burger JA; Schorcht A; Sanders RW; Carrascosa JL; Esteban M
Front Immunol; 2019; 10():2793. PubMed ID: 31867001
[TBL] [Abstract][Full Text] [Related]
29. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
[TBL] [Abstract][Full Text] [Related]
30. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.
Gómez CE; Nájera JL; Sánchez R; Jiménez V; Esteban M
Vaccine; 2009 May; 27(24):3165-74. PubMed ID: 19446187
[TBL] [Abstract][Full Text] [Related]
31. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
[TBL] [Abstract][Full Text] [Related]
32. Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen.
Hel Z; Tsai WP; Thornton A; Nacsa J; Giuliani L; Tryniszewska E; Poudyal M; Venzon D; Wang X; Altman J; Watkins DI; Lu W; von Gegerfelt A; Felber BK; Tartaglia J; Pavlakis GN; Franchini G
J Immunol; 2001 Dec; 167(12):7180-91. PubMed ID: 11739541
[TBL] [Abstract][Full Text] [Related]
33. In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses.
Huang X; Zhu Q; Huang X; Yang L; Song Y; Zhu P; Zhou P
Vaccine; 2017 Apr; 35(16):2042-2051. PubMed ID: 28318765
[TBL] [Abstract][Full Text] [Related]
34. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.
Bakari M; Aboud S; Nilsson C; Francis J; Buma D; Moshiro C; Aris EA; Lyamuya EF; Janabi M; Godoy-Ramirez K; Joachim A; Polonis VR; Bråve A; Earl P; Robb M; Marovich M; Wahren B; Pallangyo K; Biberfeld G; Mhalu F; Sandström E
Vaccine; 2011 Oct; 29(46):8417-28. PubMed ID: 21864626
[TBL] [Abstract][Full Text] [Related]
35. An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates.
Wise MC; Hutnick NA; Pollara J; Myles DJ; Williams C; Yan J; LaBranche CC; Khan AS; Sardesai NY; Montefiori D; Barnett SW; Zolla-Pazner S; Ferrari G; Weiner DB
J Virol; 2015 Sep; 89(18):9154-66. PubMed ID: 26085155
[TBL] [Abstract][Full Text] [Related]
36. Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.
Viegas EO; Kroidl A; Munseri PJ; Missanga M; Nilsson C; Tembe N; Bauer A; Joachim A; Joseph S; Mann P; Geldmacher C; Fleck S; Stöhr W; Scarlatti G; Aboud S; Bakari M; Maboko L; Hoelscher M; Wahren B; Robb ML; Weber J; McCormack S; Biberfeld G; Jani IV; Sandström E; Lyamuya E;
PLoS One; 2018; 13(11):e0206838. PubMed ID: 30496299
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates.
Saunders KO; Santra S; Parks R; Yates NL; Sutherland LL; Scearce RM; Balachandran H; Bradley T; Goodman D; Eaton A; Stanfield-Oakley SA; Tartaglia J; Phogat S; Pantaleo G; Esteban M; Gomez CE; Perdiguero B; Jacobs B; Kibler K; Korber B; Montefiori DC; Ferrari G; Vandergrift N; Liao HX; Tomaras GD; Haynes BF
J Virol; 2018 Apr; 92(8):. PubMed ID: 29437967
[TBL] [Abstract][Full Text] [Related]
38. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
[TBL] [Abstract][Full Text] [Related]
39. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
40. Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults.
Joachim A; Nilsson C; Aboud S; Bakari M; Lyamuya EF; Robb ML; Marovich MA; Earl P; Moss B; Ochsenbauer C; Wahren B; Mhalu F; Sandström E; Biberfeld G; Ferrari G; Polonis VR
PLoS One; 2015; 10(4):e0118486. PubMed ID: 25874723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
